Monday, March 27, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home CBRNE

Dried Plasma Device for CBRNE Mass Casualty Scenario

by Global Biodefense Staff
October 12, 2012

The Biomedical Advanced Research and Development Authority (BARDA) has awarded Velico Medical, Inc., a development contract worth up to $38.6 million for a device that could revolutionize emergency blood storage and shipment for use in chemical, biological, radiological, nuclear or high-yield explosive (CBRNE) or natural disaster emergencies.

The spray-dry device would convert fresh liquid blood plasma into a sterile powder for more effective shipment and storage.  Current practices of utilizing frozen plasma pose logistical limitations in a mass casualty care situation.

“The new device would enable hospitals and blood centers to convert individual plasma units into single-use packages of powder. Each package also would include a unit of rehydration fluid, separated from the powder through a connector with a breakable plug,” stated a press release from the Department of Health and Human Services. “When the plasma is needed for transfusion, the two components can be mixed by breaking the plug to reconstitute the plasma in a matter of minutes.”

Initially funding will be $8.9 million over 18-months in which Velico Medical will optimize and validate prototypes for the spray drying device and single-use plasma drying chamber. Based on performance, additional funding up to the $38.6 million total may be awarded over five years for conduct of safety and efficacy research as well as comparative studies to frozen plasma.

BARDA is seeking additional proposals for products that potentially could be used to treat illnesses and improved diagnostic tools during a CBRN incident. Proposals are accepted through the current Broad Agency Announcement, BARDA-CBRN-BAA-12-100-SOL-00011.

Tags: ASPRAwardsBARDAHHS

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy